| Symbol | NUZTF |
|---|---|
| Name | NEURIZON THERAPEUTICS LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 3000 Australia VA Suite 2, Level 11, 385 Bourke Street |
| Telephone | +1 415-572-8152 |
| Fax | — |
| — | |
| Website | https://www.neurizon.com/ |
| Incorporation | AU |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | RSM Australia Partners; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimers and Parkinsons disease. Additional info from OTC: |
No news found.